Table 1 Patient, disease and transplant characteristics.
All patients frequency (%) | |
|---|---|
N | 145 |
Gender: Male | 95 (66%) |
Age | |
Median(range), (IQR) | 52 (19–74), (41–62) |
BMI | |
Median(range), (IQR) | 28.0 (19.2–50.2), (24.9–32.1) |
Donor Type | |
Matched Sibling | 104 (72%) |
Single UCB | 9 (6%) |
Double UCB | 32 (22%) |
Conditioning | |
MAC | 63 (43%) |
RIC | 82 (57%) |
GVHD Prophylaxis | |
CsA or TAC/MTX | 51 (35%) |
CsA or TAC/MMF | 86 (59%) |
Siro/MMF | 8 (6%) |
Diagnosis | |
Acute Leukemia | 86 (60%) |
CML/CLL | 6 (4%) |
Lymphoma | 25 (17%) |
Other | 28 (19%) |
Karnofsky at HCT | |
<90 | 20 (14%) |
≥90 | 125 (86%) |
HCT-CI | |
Low Risk: 0 | 60 (41%) |
Intermediate Risk: 1-2 | 42 (29%) |
High Risk: 3+ | 43 (30%) |
ABO Recipient | |
A | 62 (43%) |
B | 13 (9%) |
AB | 3 (2%) |
O | 67 (46%) |
ABO Donor | |
A, B or AB | 75 (52%) |
O | 70 (48%) |
Year of cGVHD | |
2010–2013 | 76 (52%) |
2014–2018 | 69 (48%) |
Days from HCT to cGVHD | |
Median(range), (IQR) | 220 (88–1111), (168–309) |
Karnofsky at cGVHD: <90 | 38 (26%) |
cGVHD Type at Onset | |
De-novo | 55 (38%) |
Quiescent | 55 (38%) |
Progressive | 35 (24%) |
cGVHD Global Severity at Onset | |
Mild | 24 (16%) |
Moderate | 82 (57%) |
Severe | 39 (27%) |
Prior Acute GVHD Grade | |
No acute GVHD | 53 (37%) |
Grade I–II | 50 (34%) |
Grade III–IV | 42 (29%) |
Number of Organs involved at cGVHD Onset | |
1 or 2 | 75 (52%) |
≥3 | 70 (48%) |
WBC at cGVHD Diagnosis | |
Median(range), (IQR) x109/L | 5.9 (1.2–17.2), (4.3–7.9) |
Platelets at cGVHD Diagnosis | |
Median(range), (IQR) | 138 (3–470), (99–183) |
<100,000 ×109/L | 38 (26%) |
≥100,000 ×109/L | 107 (74%) |
cGVHD Organ Involvement | |
Skin | 60 (40%) |
Eyes | 70 (48%) |
Mouth | 107 (74%) |
Liver | 42 (29%) |
Gastrointestinal | 59 (41%) |
Genitourinary | 7 (5%) |
Lung | 5 (4%) |
Joints | 15 (10%) |
cGVHD Treatment | |
Systemic | 39 (27%) |
Topical | 12 (8%) |
Both | 94 (65%) |
